Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Assisted Reproductive Technology Market CAGR Analysis And Future Market Development
Assisted reproductive technology attained substantial market expansion recently, projecting an increase from $37.06 billion in 2025 to $40.46 billion in 2026, reflecting a compound annual growth rate of 9.2%. During the past, this growth trajectory was driven by escalating infertility rates, a trend towards later childbearing, the proliferation of fertility treatment centers, a greater availability of assisted reproductive interventions, and a societal shift towards greater acceptance of ART procedures.
The field of assisted reproductive technology is projected to experience a significant expansion in the coming years, reaching an estimated market value of $56.96 billion by 2030, driven by a compound annual growth rate of 8.9%. This anticipated growth trajectory is fueled by several key factors, including the heightened use of sophisticated fertility diagnostic tools, increased capital investment directed towards fertility treatment facilities, the broadening scope of genetic testing, a greater preference for less invasive procedures, and augmented healthcare expenditures specifically allocated to reproductive well-being. Over the projected timeframe, notable market developments are expected to include the wider implementation of cutting-edge embryo assessment methodologies, a more prevalent utilization of frozen embryo and egg preservation services, a growing consumer desire for tailored fertility interventions, the integration of genetic testing more extensively within ART processes, and a pronounced emphasis on optimizing the success rates of fertility treatments.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=5489&type=smp
Assisted Reproductive Technology Market Industry Drivers: What Is Driving Revenue Growth?
The increasing prevalence of infertility is anticipated to stimulate the assisted reproductive technology market in the foreseeable future. Infertility, characterized by the inability to achieve pregnancy following a year of regular, unprotected intercourse, impacts both genders and is commonly identified by a failure to conceive. Assisted reproductive technology (ART) serves as a treatment for infertility, encompassing fertility procedures that utilize both male and female gametes. For example, as reported by the World Health Organization (WHO) in April 2023, a significant number of individuals of reproductive age globally face infertility challenges, which consequently affect their families and communities. It is estimated that approximately 1 in 6 adults worldwide, translating to about 17.5% of the global adult population, experience infertility. Consequently, the escalating incidence of infertility directly propels the expansion of the assisted reproductive technology market.
Assisted Reproductive Technology Market Segment Analysis Highlighting Growth Areas
The assisted reproductive technology market covered in this report is segmented –
1) By Diagnosis: Hysterosalpingography, Ovarian Reserve Testing, Genetic Testing
2) By Procedure Type: Fresh Non-Donor, Fresh Donor, Frozen Donor, Frozen Non-Donor, Embryo Or Egg Banking
3) By End-User: Hospitals, Fertility Clinics, Other End-Users
Subsegments:
1) By Hysterosalpingography (HSG): X-ray HSG, Sonohysterography (SHG)
2) By Ovarian Reserve Testing: Follicle Stimulating Hormone (FSH) Testing, Anti-Müllerian Hormone (AMH) Testing, Antral Follicle Count (AFC) via Ultrasound
3) By Genetic Testing: Preimplantation Genetic Testing (PGT), Carrier Screening Tests, Genetic Compatibility Testing
#Assisted Reproductive Technology Market Growth Trends: What Is Influencing The Future Outlook?
Leading entities within the assisted reproductive technology sector are prioritizing the creation of cutting-edge diagnostic tools, namely next-generation sequencing (NGS) based testing kits, with the aim of refining chromosomal evaluations, optimizing embryo selection, and elevating the success probabilities associated with fertility interventions. This approach, often termed NGS-based preimplantation genetic testing, encompasses research-grade technologies designed for thorough evaluation of embryonic chromosomal irregularities, thus aiding critical choices made during In Vitro Fertilization (IVF) and Intracytoplasmic Sperm Injection (ICSI). A notable development occurred in July of 2023 when Thermo Fisher Scientific Inc., a prominent American biotechnology firm, introduced two NGS-powered products, the Ion ReproSeq PGT-A Kit and the Ion AmpliSeq Polyploidy Kit, specifically to facilitate preimplantation genetic testing for aneuploidy (PGT-A). These assays, developed for laboratories involved in reproductive health, represent novel research use products and are designed to integrate seamlessly with the Ion Torrent Genexus Integrated Sequencer, thereby streamlining the entire process from sample handling to aneuploidy assessment. The primary objective of PGT-A testing is to detect chromosomal abnormalities in embryonic specimens, and these newly released solutions are intended to further scientific knowledge, improve implantation and pregnancy success rates, and foster healthier beginnings for upcoming generations. The Genexus platform’s inherent capabilities simplify the research lifecycle by consolidating templating, sequencing, and data analysis, while the Ion AmpliSeq Polyploidy Panel kit furnishes advanced quality assurance mechanisms to guard against sample contamination, prevent inadvertent mix-ups, and accurately identify triploidy in embryos, collectively signifying substantial technological advancement in the assisted reproductive technology market.
Assisted Reproductive Technology Market Leading Companies: Who Holds Significant Market Presence?
Major companies operating in the assisted reproductive technology market are Cooper Surgical Inc., Ferring Pharmaceuticals Ltd., Hamilton Thorne Ltd., Merck KGaA, Genea Limited, California Cryobank, European Sperm Bank, OvaScience Inc., Bloom IVF Centre, Vitrolife AB, FUJIFILM Irvine Scientific Inc., Nidacon International AB, Monash IVF Group Ltd., Cook Medical, INVO Bioscience Inc., Thermo Fisher Scientific Inc., Anecova Sa, Carolinas Fertility Institute, Microm Ltd., Inception Sciences Inc., Progyny Inc., Oxford Gene Technology IP Ltd., IVI-RMA Global, Boston IVF, CARE Fertility Group, Virtus Health, Reproductive Medicine Associates of New York, Shady Grove Fertility, CCRM Fertility, New Hope Fertility Center, Houston Fertility Institute, Pacific Fertility Center, RMA of New Jersey, Sher Fertility Institute, IVF Florida, ORM Fertility, HRC Fertility, Arizona Center for Reproductive Endocrinology & Infertility, San Diego Fertility Center, Fertility Centers of Illinois
Access The Complete Assisted Reproductive Technology Market Report:
Assisted Reproductive Technology Market Geographic Distribution And Regional Opportunities
Europe was the largest region in the assisted reproductive technology market in 2025. North America was the second-largest region in assisted reproductive technology market. The regions covered in the assisted reproductive technology market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
